MODEL SYSTEMS SHARED RESOURCE: HISTOPATHOLOGY FACILITY (HF) PROJECT SUMMARY/ABSTRACT The Histopathology Facility (HF) facilitates research for Cancer Center members by providing them with technical processing of cells and tissues as well as helping in the interpretation of results. The HF is Co- Directed by Qi Cai, MD and Andres Klein-Szanto, MD (CB), both with experience in human and experimental animal pathology. Both of the Director pathologists, and the 2 FTE technical staff, play a major role in research projects in support of Cancer Center members. The services provided by HF are important to the establishment and characterization of human cancer and other disease models. 34 Cancer Center members used the HF in calendar year 2014. 85% of the Cancer Center member users in 2014 were peer-review funded. 56 Cancer Center members from all 5 Research Programs used the HF in the period 2011-2014. The HF prepares, processes, and assists in evaluating tissues derived from experimental protocols developed by Cancer Center members. Most of the projects involve animal models of human cancer that require complex histological and/or cytological processing to determine morphological alterations, as well as to localize cancer- relevant gene products. The most frequently utilized services of the Facility include: laboratory animal autopsy, fixation, embedding, sectioning and staining of paraffin-embedded tissues, unstained paraffin sections for immunohistochemistry (IHC), cryomicrotomy, special stains, IHC, digital microphotography, interpretative histopathology, image analysis, and laser capture microdissection. The HF also provides support to the Laboratory Animal Health Services of the Laboratory Animal Facility in quality control and animal health monitoring activities, as well as processing support to the Biosample Repository and Genomics Facilities. Cancer Center member users of HF services interact directly with the HF pathologists and technicians in order to inform and instruct them about their particular requirements. Some of these include: special orientation of tissues and embryos, serial sectioning, development of immunohistochemical procedures with new antibodies produced by in-house investigators, image analysis, quantitative histopathology, etc. All of these and custom- made approaches are not available from outside bulk histopathology companies. Institutional funds of $149,175 were utilized to upgrade the capabilities of the HF by purchasing a new Leica Microsystems Laser Capture Microdissection instrument. The HF has moved to the West Building on the main FCCC campus, to put it into closer proximity to its user base. Institutional funds of $23,500 were provided to modify the new space to make it suitable for HF work. The HF is advised by a dedicated Facility Advisory Committee (FAC) that meets annually. Recommendations from the FAC are directed to a governing Facility Parent Oversight Committee that serves to ensure that the HF continues to have the necessary resources to provide the highest quality services for Cancer Center members. Demand for services is expected to increase in the next cycle of the CCSG due to plans to recruit in all 5 Programs, and new demand from Cancer Center members at TU.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA006927-52
Application #
9331463
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2017-08-01
Budget End
2018-07-31
Support Year
52
Fiscal Year
2017
Total Cost
Indirect Cost
Name
Research Institute of Fox Chase Cancer Center
Department
Type
DUNS #
064367329
City
Philadelphia
State
PA
Country
United States
Zip Code
19111
Reese, Jennifer Barsky; Bober, Sharon L; Daly, Mary B (2017) Talking about women's sexual health after cancer: Why is it so hard to move the needle? Cancer 123:4757-4763
Peri, Suraj; Caretti, Elena; Tricarico, Rossella et al. (2017) Haploinsufficiency in tumor predisposition syndromes: altered genomic transcription in morphologically normal cells heterozygous for VHL or TSC mutation. Oncotarget 8:17628-17642
Jiang, Pengtao; Li, Yueran; Poleshko, Andrey et al. (2017) The Protein Encoded by the CCDC170 Breast Cancer Gene Functions to Organize the Golgi-Microtubule Network. EBioMedicine 22:28-43
Christian, Allison H; O'Malley, Denalee; Barac, Ana et al. (2017) Cardiovascular risk and communication among early stage breast cancer survivors. Patient Educ Couns 100:1360-1366
Heckman, Carolyn J; Kloss, Jacqueline D; Feskanich, Diane et al. (2017) Associations among rotating night shift work, sleep and skin cancer in Nurses' Health Study II participants. Occup Environ Med 74:169-175
Stepanova, Dina S; Semenova, Galina; Kuo, Yin-Ming et al. (2017) An Essential Role for the Tumor-Suppressor Merlin in Regulating Fatty Acid Synthesis. Cancer Res 77:5026-5038
Gerson, James N; Skariah, Sam; Denlinger, Crystal S et al. (2017) Perspectives of HER2-targeting in gastric and esophageal cancer. Expert Opin Investig Drugs 26:531-540
Cheung, Mitchell; Testa, Joseph R (2017) BAP1, a tumor suppressor gene driving malignant mesothelioma. Transl Lung Cancer Res 6:270-278
Kruger, Warren D (2017) Cystathionine ?-synthase deficiency: Of mice and men. Mol Genet Metab 121:199-205
Jaffe, Eileen K (2017) New protein structures provide an updated understanding of phenylketonuria. Mol Genet Metab 121:289-296

Showing the most recent 10 out of 1165 publications